# CURIS INC (CRIS) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_be38cebefdbdf9a03233 · retrieved 2026-08-11T15:50:05.046Z

## Overview
Curis, Inc. is a biopharmaceutical company engaged in the development of biological products.

On July 24, 2026, Curis, Inc. received written notice from Nasdaq indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel. The Company will be subject to a Discretionary Panel Monitor for a one-year period from July 24, 2026. During the monitor period, the Company will not be permitted to provide Staff with a plan of compliance with respect to any deficiency that arises, and Staff will not be permitted to grant additional time for the Company to regain compliance.

## Terms
- Counterparty: Nasdaq Stock Market LLC

## Key dates
- Announced 2026-07-30 · Expiry 2027-07-24

## Timeline
- 2026-07-30 · 8-K (0001108205-26-000105): 8-K - CURIS INC — *Curis, Inc. is a biopharmaceutical company engaged in the development of biological products.* On July 24, 2026, Curis, Inc. received written notice from Nasdaq indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel. The Company will be subject to a Discretionary Panel Monitor for a one-year period from July 24, 2026. During the monitor period, the Company will not be permitted to provide Staff with a plan of compliance with respect to any deficiency that arises, and Staff will not be permitted to grant additional time for the Company to regain compliance.
  https://www.sec.gov/Archives/edgar/data/1108205/0001108205-26-000105.txt

## Citations
- 0001108205-26-000105 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110820526000105